SCHEMBL3889763

SCHEMBL3889763

O=C(O)c1ccc2c(Br)cn(Cc3ccccc3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.54
SLC22A12 Q96S37 3/20 0.52
FABP4 P15090 1/20 0.49
SERPINE1 P05121 1/20 0.48
PDE4A P27815 3/20 0.47
PDE4B Q07343 3/20 0.47
PDE4C Q08493 3/20 0.47
PDE4D Q08499 3/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 1/20 0.46
MAPK10 P53779 1/20 0.46
ADORA1 P30542 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HCAR3 P49019 1/20 0.45
MEN1 O00255 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880217 0.86 CNR2 (0.57) RHEBPDE4APDE4BPDE4CPDE4D
SCHEMBL1993195 0.84 SERPINE1 (0.55) SLC22A12FABP4SERPINE1LMNAALDH1A1
SCHEMBL8599922 0.83 SLC22A12 (0.74) SLC22A12FABP4PDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL8598410 0.82 SLC22A12 (0.72) SLC22A12FABP4PDE4APDE4BPDE4C
SCHEMBL21439305 0.81 RHEB (0.67) RHEBFABP4SERPINE1LMNAALDH1A1
SCHEMBL28018754 0.77 KMT2A (0.58) LMNAALDH1A1ADORA1MEN1KMT2A
SCHEMBL2510390 0.76 LMNA (0.54) LMNAALDH1A1ADORA1MEN1KMT2A
SCHEMBL1991908 0.75 ADRA1D (0.55) SLC22A12SERPINE1PDE4APDE4BPDE4C
SCHEMBL8598408 0.74 PDE4A (0.64) SLC22A12PDE4APDE4BPDE4CPDE4D
SCHEMBL2418393 0.74 ALDH1A1 (0.46) SLC22A12ALDH1A1MAPK10MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544803-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-06-09 US disclosed
US-7544803-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-06-09 US disclosed
US-7544803-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-06-09 US disclosed
US-20050165049-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165049-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 RHEB 2105/4885SLC22A12 2522/4885FABP4 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.